Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Long-Term Investments (2016 - 2025)

Fortress Biotech has reported Long-Term Investments over the past 10 years, most recently at $17.7 million for Q4 2025.

  • Quarterly results put Long-Term Investments at $17.7 million for Q4 2025, up 583.17% from a year ago — trailing twelve months through Dec 2025 was $17.7 million (up 583.17% YoY), and the annual figure for FY2025 was $17.7 million, up 583.17%.
  • Long-Term Investments for Q4 2025 was $17.7 million at Fortress Biotech, up from $2.6 million in the prior quarter.
  • Over the last five years, Long-Term Investments for FBIO hit a ceiling of $56.9 million in Q3 2021 and a floor of $2.6 million in Q4 2024.
  • Median Long-Term Investments over the past 3 years was $23.5 million (2021), compared with a mean of $29.8 million.
  • Biggest five-year swings in Long-Term Investments: soared 110.61% in 2021 and later skyrocketed 583.17% in 2025.
  • Fortress Biotech's Long-Term Investments stood at $56.9 million in 2021, then tumbled by 95.45% to $2.6 million in 2024, then skyrocketed by 583.17% to $17.7 million in 2025.
  • The last three reported values for Long-Term Investments were $17.7 million (Q4 2025), $2.6 million (Q4 2024), and $56.9 million (Q3 2021) per Business Quant data.